BOSTON, MA — April 25, 2023— We are pleased to announce the promotion of Adam Poulin-Kerstien, JD, PhD to General Counsel & appointment of Adrian Veres, MD, PhD to Chief Scientific Officer!

Adam Poulin-Kerstien, JD, PhD, has extensive experience as a life sciences intellectual property and corporate attorney. While at Dyno, Adam defined Dyno’s IP strategy and supported Dyno’s broader legal needs as Head of Legal and member of the executive leadership team. Prior to joining Dyno, Adam worked for the Novartis Institutes for Biomedical Research where he led and coordinated IP support for Novartis’ respiratory disease and neuroscience research and development programs. Adam holds a BA in Chemistry from Amherst College, a PhD from Caltech, and a JD from UCLA School of Law.

Adrian Veres, MD, PhD is happiest combining experimental and computational biology to solve critical problems in developing the next generation of human medicines. As Dyno co-founder, his past roles include Head of People and Head of R&D. Adrian holds an A.B. in Physics and Chemistry from Harvard College, a PhD in Systems Biology from Harvard University and an MD with Honors from Harvard & MIT.

Adam and Adrian, we look forward to your leadership as we advance the frontiers of #genetherapy to transform patient lives with cutting-edge science!

About Dyno Therapeutics

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning. The company is located in Cambridge, Massachusetts. Visit for additional information.

Back to Top